Santamaria Alessandra C, Simcock James O, Kuntz Charles A
J Am Vet Med Assoc. 2019 Aug 1;255(3):345-351. doi: 10.2460/javma.255.3.345.
To evaluate adverse events and outcomes in dogs with appendicular osteosarcoma treated with limb amputation followed by a single SC infusion of carboplatin.
45 client-owned dogs with appendicular osteosarcoma treated with limb amputation and SC infusion of carboplatin between January 1, 2006, and January 15, 2017.
Medical records were reviewed, and data collected included signalment, tumor location, treatment, results of clinicopathologic analyses and diagnostic imaging, adverse effects of chemotherapy, metastasis-free interval, survival time, and communications with owners and referring veterinarians. Findings were evaluated with the Kaplan-Meier survival analysis and Mantel-Haenszel log-rank test.
45 dogs were identified that met the inclusion criteria (12 of the 45 dogs had been reported in a previous case series). No dogs had pulmonary metastases detectable by CT or radiography before treatment. All dogs completed the protocol as planned. Median survival time (MST) was 196 days; metastasis-free interval was 197 days. Three of the 45 (7%) dogs required hospitalization for gastrointestinal signs related to chemotherapy. There were no chemotherapy-related deaths.
Results indicated that although treatment with SC infusion of carboplatin was well tolerated, the MST for dogs in the present study was similar to reported MSTs in dogs with appendicular osteosarcoma treated with limb amputation alone and was in the lower range of historically reported survival times for dogs receiving IV adjunctive chemotherapy. Therefore, we could not recommend this protocol of SC infusion of carboplatin but recommended that protocols with IV administration of carboplatin be used instead.
评估接受肢体截肢术并随后单次皮下注射卡铂治疗的犬附肢骨肉瘤的不良事件和预后。
2006年1月1日至2017年1月15日期间，45只客户拥有的患有附肢骨肉瘤的犬接受了肢体截肢术和皮下注射卡铂治疗。
查阅病历，收集的数据包括特征、肿瘤位置、治疗、临床病理分析和诊断成像结果、化疗不良反应、无转移间期、生存时间以及与主人和转诊兽医的沟通情况。采用Kaplan-Meier生存分析和Mantel-Haenszel对数秩检验对结果进行评估。
确定45只犬符合纳入标准（45只犬中有12只曾在先前的病例系列中报道过）。治疗前通过CT或X线检查未发现犬有肺转移。所有犬均按计划完成方案。中位生存时间（MST）为196天；无转移间期为197天。45只犬中有3只（7%）因化疗相关的胃肠道症状需要住院治疗。无化疗相关死亡病例。
结果表明，尽管皮下注射卡铂治疗耐受性良好，但本研究中犬的MST与仅接受肢体截肢术治疗的附肢骨肉瘤犬的报道MST相似，且处于接受静脉辅助化疗犬的历史报道生存时间的较低范围。因此，我们不推荐这种皮下注射卡铂的方案，而是建议使用静脉注射卡铂的方案。
